U.S. Food and Drug Administration staffers on Tuesday expressed continued caution over the use of anemia drugs sold by Amgen
, according to an agency document released on Tuesday.
More data is needed on the risks with the drugs, which include Amgen's Aranesp and Epogen and J&J's Procrit, the agency staff said. Changes to the products' labeling may also be appropriate, they added.
The document was released ahead of an FDA advisory panel meeting on Thursday to discuss the risks of using the erythropoiesis-stimulating agents in cancer patients.